Clinical Trials Sponsored by Keyrus Biopharma

Total 1444 results

Mereo BioPharma
Novartis

Terminated

A Safety & Efficacy Study of BGS649 in Women With Refractory Endometriosis

Pelvic Pain Associated With Refractory Endometriosis

United States, Puerto Rico
Mereo BioPharma
Novartis

Terminated

Safety & Efficacy of BCT197 in Patients Undergoing Cardiac Surgery

Acute Kidney Injury

Taiwan, United States, Israel
ReveraGen BioPharma, Inc.

Withdrawn

Proof of Concept Trial of Vamorolone in Pediatric Ulcerative Colitis

Pediatric Ulcerative Colitis
Therapure Biopharma Inc

Unknown

Study of PlasmaCap IG in Adults and Children With PIDD

Primary Immune Deficiency Diseases (PIDD)

United States, Canada
Acrotech Biopharma Inc.

Withdrawn

Phase 1 Study of Fusilev® to Prevent or Reduce Mucositis in Patients With Non-Small Cell Lung Cancer Receiving Folotyn®

Non-Small Cell Lung Cancer
Acrotech Biopharma Inc.

Completed

Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies

B-cell Lymphoma | Hodgkin's Lymphoma | Relapsed or Refractory Lymphoproliferative Malignancies | Peripheral T-cell Lymphoma | Waldenstrom's Macroglobulinemia

United States
Acrotech Biopharma Inc.

Completed

Study of Pralatrexate in Female Patients With Previously-treated Breast Cancer

Breast Cancer | Breast Tumors | Neoplasms, Breast | Cancer of the Breast | Human Mammary Carcinoma

France, United States, Czechia, Hungary
Alios Biopharma Inc.

Completed

A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of the Combination of AL-335, Odalasvir, and Simeprevir

Chronic Hepatitis C

New Zealand, Moldova, Republic of, Mauritius, United Kingdom
Alios Biopharma Inc.

Completed

A Study of ALS-008176 in Infants Hospitalized With RSV

Respiratory Syncytial Virus Infections

United States, Taiwan, Australia, Canada, United Kingdom, Colombia, France, New Zealand, Japan, South Africa, Chile, Panama, Romania, Thailand
RedHill Biopharma Limited

Completed

BEKINDA (Ondansetron 24 mg Bimodal Release Tablets) for Vomiting Due to Presumed Acute Gastroenteritis or Gastritis (GUARD)

Gastritis | Gastroenteritis

United States
iX Biopharma Ltd.

Completed

Study of Wafermine™ for Post-bunionectomy or Abdominoplasty Pain

Acute Pain | Bunion | Abdominoplasty

United States
Arbutus Biopharma Corporation

Completed

Study of ARB-001467 in Subjects With Chronic HBV Infection Receiving Nucleos(t)Ide Analogue Therapy

Hepatitis B, Chronic

Australia, New Zealand
Alios Biopharma Inc.

Completed

A Drug-Drug Interaction Study to Evaluate the Effect of AL-794 on the Pharmacokinetics of Oseltamivir and JNJ-63623872

Influenza in Humans

United Kingdom
Can-Fite BioPharma

Completed

Oral CF101 Tablets and Methotrexate Treatment in Rheumatoid Arthritis Patients

Rheumatoid Arthritis

Israel, Czechia, Bulgaria, Poland, Serbia, Ukraine
Alios Biopharma Inc.

Completed

A Phase 1, Open-Label Study of the Absorption, Metabolism, Excretion and Absolute Bioavailability of ALS-008176

Respiratory Syncytial Virus Infections

United Kingdom
Alios Biopharma Inc.

Completed

A Phase 2a Study to Evaluate Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus

Respiratory Syncytial Virus Infections

Australia, Singapore, United States, New Zealand, Taiwan
Alios Biopharma Inc.

Completed

A Study of AL-794 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses, and the Antiviral Activity of Multiple Doses in an Influenza Challenge Study

Influenza

United Kingdom
Hansa Biopharma AB

Completed

Phase II Study, Evaluation of Safety and Efficacy of IdeS in Chronic Kidney Disease

Chronic Kidney Disease

Sweden
iX Biopharma Ltd.

Completed

Crossover Study to Evaluate the PK Effects of Two Different Wafer Administration Protocols.

Pain

Australia
Veloce BioPharma LLC

Completed

ALC-919 For The Treatment Of Common Warts

Verruca Vulgaris

United States
Alios Biopharma Inc.

Completed

A Phase 2a Study to Evaluate ALS-008176 in the Virus Challenge Model

Respiratory Syncytial Virus Infections

United Kingdom
S1 Biopharma, Inc.

Completed

Phase 1b/2a Unblinded Study of Responses in Premenopausal Women With HSDD to Lorexys Evaluating Efficacy and Safety (PURPLE)

Hypoactive Sexual Desire Disorder (DSM-IV-TR Defined) | Sexual Interest/Arousal Disorder (DSM-5 Defined)

United States
ARCA Biopharma, Inc.

Completed

Trial of a Novel Fibrinolytic (Alfimeprase) to Clear Thrombosed Vascular Access Devices

Catheters, Indwelling

United States
Arbutus Biopharma Corporation

Terminated

Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Liposomal siRNA in Subjects With High Cholesterol

Hypercholesterolemia

United States
Ambrilia Biopharma, Inc.

Completed

Open Label Extension Study Evaluating Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients

Acromegaly

Belarus, Hungary, Serbia, Ukraine, Romania, Slovakia
ARCA Biopharma, Inc.

Suspended

Safety Study of Recombinant NAPc2 to Prevent Tumor Progression and Metastases in Metastatic Colon Cancer

Colon Cancer

United States
ARCA Biopharma, Inc.

Terminated

Phase 2 Proof-of-Concept Study of the Safety and Efficacy of Alfimeprase to Rapidly Open Arteries and Restore Brain Function Following a Stroke

Acute Ischemic Stroke

United States, Canada
ARCA Biopharma, Inc.

Completed

Study of Alfimeprase to Rapidly Dissolve Blood Clots in the Leg and Help Prevent the Need for Surgery on Leg Arteries

Arterial Occlusive Diseases

United States
Arbutus Biopharma Corporation

Not yet recruiting

Long-Term Follow-up Study for Subjects With CHB Previously Treated With Imdusiran (AB729)

Long Term Follow-up

United States, Australia, Hong Kong, Taiwan, United Kingdom, Korea, Republic of, Moldova, Republic of
Benitec Biopharma, Inc.

Recruiting

A Study to Evaluate the Safety and Clinical Activity of Intramuscular Doses of BB-301 Administered to Subjects With Oculopharyngeal Muscular Dystrophy With Dysphagia

Oculopharyngeal Muscular Dystrophy

United States
UniQure Biopharma B.V.

Not yet recruiting

Safety, Tolerability, and Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Amyotrophic Lateral Sclerosis (ALS) Patients With SOD1 Mutations

Amyotrophic Lateral Sclerosis
Arbutus Biopharma Corporation

Recruiting

Safety, Tolerability, PK & PD of AB-101 Following Oral Administration in Healthy and CHB Subjects.

Chronic Hepatitis b

New Zealand
Hansa Biopharma AB

Recruiting

A Long-term Follow-up Trial of Patients Previously Treated With Imlifidase Prior to Kidney Transplantation and a Non-comparative Transplanted Patient Group (PAES-LTFU)

Long Term Efficacy and Safety

Spain, Czechia
Landos Biopharma Inc.

Recruiting

Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis

Ulcerative Colitis

United States, Belgium, Italy, Poland
Artax Biopharma Inc

Recruiting

Proof of Concept Study of AX-158 in Patients With Mild to Moderate Plaque Psoriasis

Psoriasis | Plaque Psoriasis

United Kingdom
GC Biopharma Corp

Recruiting

A Study to Evaluate the Safety, PK of GC2129A in Healthy Volunteers Under Fasting Conditions

Healthy Volunteers

Korea, Republic of
GC Biopharma Corp

Not yet recruiting

An Open-label, Bridging Study of BARYCELA Inj. in Healthy Vietnamese Children Aged Between 12 Months to 12 Years

Varicella Zoster Virus Infection
Hansa Biopharma AB

Recruiting

Efficacy and Safety in Imlifidase Desensitized Kidney Tx Patients, Including Two Non-Comparative Reference Cohorts (PAES)

Kidney Transplantation in Highly Sensitized Patients

Germany, Spain, Italy, France, Netherlands, Belgium, Austria, Czechia, Sweden, United Kingdom, Slovenia
ArriVent BioPharma, Inc.

Recruiting

Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

Advanced Non-Small Cell Lung Cancer | Metastatic Non-Small Cell Lung Cancer | Non-Small Cell Lung Cancer (NSCLC) | HER2 Exon 20 Mutations | EGFR Exon 20 Mutations | EGFR Uncommon Mutations, Including G719X and S768I

United States, Australia, Spain, Italy, United Kingdom, France, China, Korea, Republic of, Canada, Japan, Netherlands
Sutro Biopharma, Inc.

Recruiting

A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Ovarian Carcinoma | Ovary Cancer | Primary Peritoneal Carcinoma

United States
Prestige Biopharma Limited

Recruiting

To Compare the Pharmacokinetics and Safety of PBP1502 and Humira in Healthy Subjects

Healthy Volunteers

Spain
RedHill Biopharma Limited

Not yet recruiting

Evaluate Safety and Efficacy of Rifamycin SV MMX in the Treatment of Traveler's Diarrhea in Children Age 6 to 11 Years

Traveler's Diarrhea
XEME Biopharma Inc.

Not yet recruiting

Oncoquest-L Vaccine in Patients With Previously Untreated Stage III or IV, Asymptomatic, Non-bulky Follicular Lymphoma

Follicular Lymphoma

United States
Hansa Biopharma AB

Completed

An Efficacy and Safety Study of Imlifidase in Treatment of Antibody-Mediated Rejection in Kidney Transplant Patients

Kidney Transplant Rejection

Australia, United States, Germany, France, Austria
Hansa Biopharma AB

Active, not recruiting

A Study to Investigate DSA Rebound in Patients Treated With Imlifidase Prior to Transplantation

Kidney Transplantation in Highly Sensitized Patients

United States
Acrotech Biopharma Inc.

Completed

This Study is to Assess the Efficacy of Difamilast Ointment in Mild to Moderate Atopic Dermatitis(AD)

Atopic Dermatitis

United States
Can-Fite BioPharma

Completed

Oral CF101 and Methotrexate Treatment in Rheumatoid Arthritis Patients

Rheumatoid Arthritis

United States, Bulgaria, Israel, Poland, Romania, Serbia, Ukraine
CTI BioPharma
Covance

Completed

Drug-Interaction Study to Evaluate the Effect of Rifampin, a Potent CYP3A4 Inducer, on the Systemic Exposure of Pacritinib in Healthy Subjects

Healthy Subjects

United States
Hansa Biopharma AB

Terminated

An Long-term Follow-up Trial of Kidney Tx Patients Treated With Imlifidase or PE After an AMR

Kidney Transplant Rejection

Germany, France, Austria
Prestige Biopharma Limited

Completed

To Demonstrate Equivalent Pharmacokinetic Properties of HD204 and Bevacizumab (Avastin®) in Healthy Male Subjects

Healthy Volunteers

New Zealand

3

Subscribe